HPV Vaccination for MSM: Synthesis of the evidence and recommendations from the Québec Immunization Committee

Sauvageau, Chantal; Dufour-Turbis, Christine

doi:10.1080/21645515.2015.1112474

Cited by 13 publications

(4 citation statements)

References 43 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the stress of being in the minority, they cannot easily disclose their sexual orientation to the doctor and seek help. Health professionals should devote attention to reducing MSM stigma, which is a challenging problem ( Sauvageau and Dufour-Turbis, 2016 ). STDs department can cooperate with community-based organizations (CBO), and CBO staff can help MSM eliminate the shame of sexual minorities through peer education, which can increase MSM’s trust in doctors at the same time.…”

Section: Discussionmentioning

confidence: 99%

Improving the Acceptability of Human Papillomavirus Vaccines Among Men Who Have Sex With Men According to the Associated Factors: A Systematic Review and Meta-analysis

et al. 2021

View full text Add to dashboard Cite

Objectives: To investigate the acceptability of human papillomavirus (HPV) vaccination among men who have sex with men (MSM) and its associated factors.Methods: We searched studies written in English in PubMed, EMBASE, and Web of Science with no geographical or time restrictions. We evaluated the quality of the included literature. We calculated the pooled acceptability and performed meta-analysis of selected studies, including factors associated with the acceptability among MSM, using Review Manager (v5.3).Results: The acceptability among the 15 studies (n = 8,658) was 50% (95% CI: 0.27–0.72). The meta-analysis of seven articles (n = 4,200) indicated that having a college or higher degree (OR = 1.62, 95% CI: 1.35–1.95), disclosure of sexual orientation to healthcare professionals (HCPs; OR = 2.38, 95% CI: 1.47–3.86), vaccination with at least one dose for hepatitis A or B (OR = 2.10, 95% CI: 1.42–3.10), awareness of HPV (OR = 1.85, 95% CI: 1.21–2.83), knowledge of HPV (SMD = 0.28, 95% CI: 0.16–0.39), perceived susceptibility to HPV infection (SMD = 0.31, 95% CI: 0.11–0.50), and perceived severity of HPV-related disease (SMD = 0.40, 95% CI: 0.28–0.51) can promote acceptance of HPV vaccines. Meanwhile, people who have had unprotected anal sex or have more sex partners tend to have low acceptance of HPV vaccines.Conclusions: HPV education should be actively promoted according to the factors that influence the acceptability of HPV vaccines among the MSM population. HPV education should be especially aimed at people with low academic qualifications and people with risky sexual behaviors, and should emphasize the aspects of susceptibility to and severity of HPV-related disease. More intervention trials should be conducted to increase the credibility of the results.

show abstract

Section: Discussionmentioning

confidence: 99%

Improving the Acceptability of Human Papillomavirus Vaccines Among Men Who Have Sex With Men According to the Associated Factors: A Systematic Review and Meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Some men perceived targeted HPV vaccination in MSM as discriminatory and unjust, which could lead to prejudice and marginalisation. Furthermore, targeted HPV vaccination delivered through schools was not perceived as acceptable, which may prove problematic for current targeted school-based programmes (Sauvageau et al, 2016).…”

Section: "I Don't Want To Reveal My Sexual Orientation and If The Leamentioning

confidence: 99%

Perceptions of HPV and attitudes towards HPV vaccination amongst men who have sex with men: A qualitative analysis

Nadarzynski

Smith

Richardson

et al. 2017

British J Health Psychol

View full text Add to dashboard Cite

Most MSM have poor knowledge about HPV and associated anal cancer. Despite the lack of concern about HPV, most MSM expressed willingness to receive HPV vaccination. There is a need for health education about the risks of HPV and HPV-related diseases so that MSM can appraise the benefits of being vaccinated. Concerns about HPV vaccine effectiveness in sexually active men and possible stigmatization need to be addressed to optimize HPV vaccine acceptability. Statement of contribution What is already known on this subject? Men who have sex with men (MSM) have poor knowledge about HPV and HPV-related diseases. Perceived risk of HPV and attitudes towards HPV vaccination are associated with HPV vaccine acceptability amongst MSM in the United States. There is a gap between acceptability and uptake of HPV vaccination amongst MSM. What does this study add? Due to concerns about compromised effectiveness of the HPV vaccine in sexually active men, most MSM would recommend vaccination of all adolescent boys. Restricted access to sexual health services and the inability to discuss same-sex experiences were perceived as barriers to HPV vaccination. While the HPV vaccine is acceptable amongst MSM, the motivation to be vaccinated and complete the three-dose series might be low.

show abstract

“…Vaccinating women can protect heterosexual men, but this herd protection does not extend to MSM and bisexual men [ 49 ]. Not considering this group for vaccination can contribute to an increase HPV-related diseases, especially anogenital cancer [ 50 , 51 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of Human Papillomavirus Vaccination on Male Disease: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Human papillomavirus (HPV)-related diseases are highly prevalent in men worldwide, comprising external anogenital condyloma, anal intraepithelial neoplasia (AIN), penile intraepithelial neoplasia (PIN), and anogenital and oropharyngeal cancers. There is exceptionally low vaccine coverage in the male population. Only 4% of men were fully vaccinated, worldwide, as of 2019. The aim of this review is to assess the impact of HPV vaccination on male disease. Three databases (MEDLINE, Web of Science, Scopus) and Clinical Trials.gov were searched. We included thirteen studies, eight randomized controlled trials (RCTs), and five cohorts, comprising a total of 14,239 participants. Regarding anal disease, seven studies reported HPV vaccine efficacy ranging from 91.1% to 93.1% against AIN1, and ranging from 89.6% to 91.7% against AIN2|3 and anal cancer. Five studies showed an efficacy against genital condyloma of 89.9% in HPV-naïve males, varying between 66.7% and 67.2% in intention-to-treat populations. Studies reporting no efficacy have included older participants. These results support vaccination of young men previously infected, beyond HPV-naïve males. The evidence quality was moderate to low for most outcomes, namely genital diseases. RCTs are needed to assess the efficacy of HPV vaccination on male oropharyngeal cancer.

show abstract

HPV Vaccination for MSM: Synthesis of the evidence and recommendations from the Québec Immunization Committee

Cited by 13 publications

References 43 publications

Improving the Acceptability of Human Papillomavirus Vaccines Among Men Who Have Sex With Men According to the Associated Factors: A Systematic Review and Meta-analysis

Improving the Acceptability of Human Papillomavirus Vaccines Among Men Who Have Sex With Men According to the Associated Factors: A Systematic Review and Meta-analysis

Perceptions of HPV and attitudes towards HPV vaccination amongst men who have sex with men: A qualitative analysis

Impact of Human Papillomavirus Vaccination on Male Disease: A Systematic Review

Contact Info

Product

Resources

About